Bio-Rad

The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents. 

The firm's topline performance for the full year was also higher than previous guidance provided by the company and analyst estimates.

A jury in Northern California has found that Sanford Wadler was wrongfully terminated and awarded him back pay and punitive damages.

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.

Systems will ship in early February and include droplet-based library prep and analytics functionalities.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.

The firm reported revenues of $508.7 million, thanks largely to an 18 percent increase in sales from the company's life science segment. 

The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.

Pages

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.